Abbvie seeks to block copycat of endometriosis drug

Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

Generics

Bayer granted 10-day injunction in blood clot drug dispute

28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.

Generics

‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole

18 February 2024 While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.

More features

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Abbvie seeks to block copycat of endometriosis drug

More on this story

Editor's picks

Editor's picks

More features